EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

Min-Wai Lwin iD, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues-van Tol und 9 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70388 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Min-Wai Lwin und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Breast Neoplasms, Cost-Effectiveness Analysis, Certification. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund of the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Germany, the German Cancer Society (Deutsche Krebsgesellschaft [DKG]) accredits hospitals to ensure high‐quality cancer treatment through adherence to clinical guidelines and a multidisciplinary approach. Evidence suggests certified hospitals (CHs) achieve better clinical outcomes and prognoses than non‐certified hospitals (NCHs). However, additional services required for certification incur substantial, unreimbursed costs, necessitating a focused cost‐effectiveness evaluation. This retrospective cohort study utilized anonymized administrative routine healthcare data from Allgemeine Ortskrankenkasse, Germany's largest statutory health insurance. The study sample comprised 143,720 incident breast cancer (BC) patients treated between 2009 and 2017 across both CHs and NCHs. A health system perspective was used in this cost‐effectiveness analysis. Direct medical costs (inpatient, outpatient, medication, and certification) were compared between CHs and NCHs. Life‐years gained (LYG) were calculated from 5‐year restricted mean survival time. The incremental cost‐effectiveness ratio (ICER), quantified as cost per LYG, served as the primary outcome measure, reported in 2024 euro. Treatment in CHs significantly improved breast cancer survival, yielding 201 LYG per 1000 patients (95% confidence interval: 185–216). Accounting for €1.5 M in certification‐related costs and marginal direct medical costs, the total incremental cost was €1.81 M per 1000 patients. This resulted in an ICER of €9036 per LYG. Despite the financial investment required for DKG certification, BC treatment in CHs provided significant survival benefits at a reasonable incremental cost, reinforcing the clinical and economic value. These findings offer critical insights for hospital authorities and healthcare policymakers, supporting the continued investment in certification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisBreast NeoplasmsCost-Effectiveness AnalysisCertificationHospitalsHumansFemaleGermanyRetrospective StudiesMiddle AgedAged

Stichwörter der Autor:innen

breast cancerbreast cancer treatment costcancer center certificationcertified hospitalscost‐effectiveness analysis

Autor:innen und Institutionen

  • Division of Health Economics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Center for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
  • Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany.
  • National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-R…
  • Tumorzentrum Regensburg, Zentrum für Qualitätssicherung und Versorgungsforschung der Universität Regensburg, Regensburg, Germany.

ORCID-Profile: Min-Wai Lwin

Förderung

  • Innovation Fund of the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA)

Zitieren

APA

Lwin, M. W., Schoffer, O., Streissnig, C., Wimberger, P., Gerken, M., Bierbaum, V., Bobeth, C., Rößler, M., Dröge, P., Ruhnke, T., Günster, C., Tol, K. K., Link, T., Scharl, A., Sturm-Inwald, E. C., Kast, K., Papathemelis, T., Ortmann, O., Klinkhammer-Schalke, M., …, & Schlander, M. (2026). A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany. International Journal of Cancer. https://doi.org/10.1002/ijc.70388

Vancouver

Lwin MW, Schoffer O, Streissnig C, Wimberger P, Gerken M, Bierbaum V, et al. A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany. International Journal of Cancer. 2026. doi:10.1002/ijc.70388

BibTeX
@article{Lwin2026,
  author = {Lwin, Min-Wai and Schoffer, Olaf and Streissnig, Christoph and Wimberger, Pauline and Gerken, Michael and Bierbaum, Veronika and Bobeth, Christoph and Rößler, Martin and Dröge, Patrik and Ruhnke, Thomas and Günster, Christian and Tol, Kees Kleihues-van and Link, Theresa and Scharl, Anton and Sturm-Inwald, Elisabeth C and Kast, Karin and Papathemelis, Thomas and Ortmann, Olaf and Klinkhammer-Schalke, Monika and Schmitt, Jochen and Schlander, Michael},
  title = {A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70388}
}
Kostenlos starten →